logo-loader
viewCelavie Biosciences

Celavie Biosciences advancing its five year exploratory study in Parkinson's Disease

Celavie Biosciences CEO Sandy Solomon sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York. The California-based company is developing regenerative stem cell therapies to treat Parkinson’s disease and other central nervous system disorders.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Covid Technologies looking for large growth after being...

Micron Waste Technologies (CSE: MWM- OTC: MICWF) soon to be subsidiary COVID Technologies President Harvey Sidhu joined Steve Darling from Proactive Vancouver to discuss his company being acquired by Micron. Sidhu discusses his company which makes PPE or personal protective equipment....

6 hours, 36 minutes ago

2 min read